Labcorp (LH) Tops Q2 EPS by 26c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Labcorp Announces 2022 Second Quarter Results
July 28, 2022 7:00 AM EDTCompany To Spin-Off Clinical Development Business
Revenue: Q2 of $3.7 billion versus $3.8 billion last year Diluted EPS: Q2 of $3.87 versus $4.76 last year Adjusted EPS: Q2 of $4.96 versus $6.13 last year Free Cash Flow: Q2 of $429 million versus $390 million last year Launched innovative diagnostics for skin cancer, neurodegenerative disease, fertility and COVID-19 Full-Year 2022 Guidance: Adjusted EPS raised to $19.00 to $21.25BURLINGTON, N.C.--(BUSINESS... More
